Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Update

Century Therapeutics, Inc. (NASDAQ:IPSC) saw a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,710,000 shares, a decline of 5.6% from the November 30th total of 2,870,000 shares. Based on an average daily trading volume, of 545,600 shares, the short-interest ratio is presently 5.0 days. Approximately 7.8% of the shares of the stock are short sold.

Century Therapeutics Stock Up 1.0 %

NASDAQ IPSC opened at $1.01 on Thursday. The firm has a market cap of $85.88 million, a P/E ratio of -0.55 and a beta of 1.65. Century Therapeutics has a 52-week low of $0.95 and a 52-week high of $5.51. The business’s 50-day moving average price is $1.31 and its 200 day moving average price is $1.74.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. The company had revenue of $0.79 million during the quarter, compared to analysts’ expectations of $0.47 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. During the same quarter last year, the business earned ($0.55) EPS. As a group, analysts anticipate that Century Therapeutics will post -1.63 earnings per share for the current year.

Institutional Investors Weigh In On Century Therapeutics

A number of institutional investors have recently added to or reduced their stakes in IPSC. Bank of New York Mellon Corp raised its stake in shares of Century Therapeutics by 110.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock worth $380,000 after buying an additional 78,088 shares in the last quarter. Rhumbline Advisers raised its position in Century Therapeutics by 56.0% in the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after acquiring an additional 18,828 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Century Therapeutics by 141.7% in the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock valued at $192,000 after acquiring an additional 44,155 shares during the period. Renaissance Technologies LLC boosted its position in shares of Century Therapeutics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after purchasing an additional 9,500 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Century Therapeutics during the 3rd quarter worth $27,000. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Piper Sandler reduced their target price on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a report on Monday. HC Wainwright reduced their price objective on Century Therapeutics from $9.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Chardan Capital lowered their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Century Therapeutics has a consensus rating of “Buy” and a consensus target price of $10.00.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.